Overview

* Rallybio ( RLYB ) Q2 revenue dips to $0.2 mln from $0.3 mln in 2024

* Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024

* Co sells REV102 interest for up to $25 mln, extending cash runway

Outlook

* Rallybio ( RLYB ) expects RLYB116 study data in 3Q and 4Q 2025

* Company's cash runway extended into mid-2027 after REV102 sale

* Rallybio ( RLYB ) anticipates complete complement inhibition in RLYB116 study

* Company focuses RLYB116 on PTR and APS conditions

Result Drivers

* REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson & Johnson

* R&D EXPENSES DROP - Lower R&D expenses due to decreased development costs for RLYB212 and other programs

* CASH INFUSION - Sale of REV102 interest to Recursion Pharmaceuticals extends cash runway into mid-2027

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$9.70

Income mln

Q2 Basic -$0.22

EPS

Q2 -$10.06

Income mln

From

Operatio

ns

Q2 $10.27

Operatin mln

g

Expenses

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)